Teva Launches Oral Drug for Schizophrenia, Bipolar I


Teva Pharmaceutical Industries announced on Monday the commercial launch of what it says is the first orally inhaled medicine for the treatment of schizophrenia or bipolar I disorder in adults, Globes reported.

Teva claims Adasuve (loxapine) inhalation 10 mg powder has been demonstrated effective in reducing agitation in patients within two hours, and as early as 10 minutes after use, in clinical trials.

Belmont Center for Comprehensive Treatment Philadelphia, Pennsylvania medical director for research and clinical trials Dr. Richard Jaffe who was a clinical trial investigator, said, “Existing treatment options for patients with agitation associated with schizophrenia or bipolar I disorder are limited to oral tablets or injectable modes of administration, sometimes requiring the use of restraints. Adasuve is a drug-device combination that offers health care providers a new option to help manage agitation.”

Agitation associated with schizophrenia and bipolar I disorder is results in an estimated 7million episodes that require an acute emergency treatment setting each year.

Due to the risk of bronchospasm that could lead to respiratory difficulty, Adasuve should not be used by patients with asthma, chronic obstructive pulmonary disease (COPD), or other pulmonary disease associated with bronchospasm.